Barron: GSK, an active embrace of change US), it's time to buy

While gsk.us has been a laggard among major pharmaceutical companies over the past decade, aggressive investor action and plans to divest its consumer health business could change the company's fortunes. According to Barron's, pressure from hedge fund Elliott Management prompted the British pharmaceutical company to make changes. The media said that as a result, the stock will be worth buying.

GlaxoSmithKline shares have fallen 9.6% over the past 10 years; Down 10.9% in the last 5 years; That's up 9.1 percent so far this year. The stock's rally this year began in mid-April, at the same time as reports that Elliott Management had secured a multibillion-pound stake in the pharmaceutical company.

CEO Emma Walmsley admitted to Barron's that GlaxoSmithKline didn't deliver shareholder returns, but the divested company would have done better. "We look forward to taking responsibility for this," she said. It is reported that in June this year, emma Walmsley said that after the divestiture of the consumer health business, "New GlaxoSmithKline" will have a stronger balance sheet and position itself as a growth company.

According to a May report, Elliott Management is clearly unhappy with Emma Walmsley at the helm: Elliott Management doesn't seem to believe the CEO knows enough about the company's pharmaceutical and vaccine businesses because it has nothing to do with her background. Emma Walmsley was a former L'Oréal executive.

Barron's said: "Investors don't need to choose a position in this quarrel." "Importantly for investors, this hedge fund has shown that it has patience and a track record of winning value for biopharmaceutical investors."